Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NPS Pharmaceuticals, Inc.

http://www.npsp.com

Latest From NPS Pharmaceuticals, Inc.

Stockwatch: Can Gilead Wave Its Wand Over Antibody-Drug Conjugates?

After a slow start marked by product withdrawals and toxicity, recent deal-making activity has brought antibody-drug conjugates back from obscurity. But what has changed?

Platform Technologies M & A

Finance Watch: Brent Saunders Plots Return To Deal-Making With A SPAC IPO

Public Company Edition: The former Allergan CEO is taking a special purpose acquisition corporation public to generate $460m for deals in familiar biopharma niches. Also, IPOs are expected to keep up a robust pace in the fall and Albireo raises $160m on the success of its drug for pediatric liver diseases.

Financing Business Strategies

Asia Deal Watch: Takeda Will Employ Engitix’s ECM Tech In Liver Fibrosis Indications

Takeda’s collaboration with the private UK biotech includes NASH and other liver disorders. Reliance will take on Amazon in the India pharmacy space with acquisition of Netmeds.

Deals Business Strategies

Albireo Exits NASH, But Has Best-In-Class IBAT Opportunity

Elobixibat demonstrated ability to reduce LDL cholesterol but is being discontinued in NASH due to its unspectacular overall profile. The firm is staying focused on odevixibat, which could be best-in-class for pediatric liver indications, analysts say.

Clinical Trials Business Strategies
See All

Company Information

UsernamePublicRestriction

Register